Alterações metabólicas nas leucemias agudas

Abstract

Objetives: Analise the occurrence of disorder in glucose metabolism in several phases of Acute Lymphoblastic Leukemia treatment, relating these disorders to unfavorable events occurred during treatment, to immunophenotypic profile, to attacks target organs, to outcome after treatment and compare with patients with Acute Myeloid Lekemia, who don’t use corticosteroids during the treatment. Methods: We studied patients up to incomplete 19 years old, in treatment for acute lymphoblastic leukemia according to the protocols GBTLI-99 or BFM-95. We obtained clinical, anthropometric and laboratory data, as well as records of complications, recurrences and deaths during the observation period. Results: The study included 80 patients with ALL, 50 (62,5%) were male. The mean age at diagnosis was 9.31 years (SD = 5,14, range: 8 months to 18 years). There was a statistically significant difference between groups with and without hyperglycemia as compared to corticosteroids (p = 0,024), which does not occur for the same variables in subsequent measurements. 29 Conclusion: In spite of being associated with laboratory abnormalities, the occurrence of hyperglycemia is not associated with adverse outcomes in children and adolescents treated for ALL.